@Article{,
AUTHOR = {Jack Barkin, Christine Folia},
TITLE = {Emerging therapies: what’s new is old and  what’s old is new},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {19},
YEAR = {2012},
NUMBER = {Suppl.5},
PAGES = {49--53},
URL = {http://www.techscience.com/CJU/v19nSuppl.5/63027},
ISSN = {1488-5581},
ABSTRACT = {Researchers are constantly seeking ways to improve 
existing drugs, drug mechanisms of activity, find new 
indications for old drugs or to develop new drugs to treat 
urological diseases and conditions. In Canada, tadalafil in 
a 5 mg daily dosage (old drug), and a new drug, silodosin, 
have recently become available to treat patients who have 
benign prostatic hyperplasia (BPH) with lower urinary 
tract symptoms (LUTS). In clinical studies, silodosin has 
shown promise as a treatment for ureteral stones, whereas 
it has shown conflicting results as a potential treatment 
for prostatitis. Two new therapies have emerged for 
treating overactive bladder (OAB): Mirabegron (not yet 
available in Canada) and fesoterodine (newly introduced 
in the marketplace). New therapies—denosumab (to 
prevent skeletal events) and abiraterone acetate and 
enzalutamide—were recently approved to treat certain 
patients with advanced prostate cancer. With the advent 
of new therapies to treat urological diseases, in many 
cases, primary management of the patient is often shifted 
from the urologist to the family physician, and sometimes 
moved from the oncologist to the urologist.},
DOI = {}
}